Releases Geral
Nyxoah to Participate in the Piper Sandler 35th Annual Healthcare Conference
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 21 de novembro de 2023
Nyxoah
Nyxoah to Participate in the Piper Sandler 35th Annual Healthcare Conference
Mont-Saint-Guibert, Belgium November 21, 2023, 10:30pm CET / 4:30pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference, which takes place November 28 30, 2023 in New York.
Olivier Taelman, Nyxoahs Chief Executive Officer, will be participating in a Fireside Chat on Wednesday, November 29, 2023, at 2:30pm ET. A webcast of the presentation will be available on the Events section of Nyxoahs Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the event.
Nyxoahs Investor Presentation can be accessed on the Shareholder Information section of the Companys Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoahs lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the worlds most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313
Attachment
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Economia Charlie transforma hotéis em opções rentáveis para locação flexível
20 de março de 2023Com mais de dois anos de atuação, a startup já opera três empreendimentos hoteleiros convertidos em short stay em São Paulo e Porto Alegre e tem previsão para entrar no Rio de Janeiro ainda
Saiba Mais -
Releases Geral Podcast-se: episódio com Daniel Milagres vai ao ar
2 de outubro de 2023DINO DIVULGADOR DE NOTÍCIAS (DINO – 02 out, 2023) – Lançado em 28/09, o novo episódio do podcast oferece discussões sobre as tendências e estratégias no
Saiba Mais -
Releases Geral OnHead Automação anuncia modelo de franquia
14 de julho de 2023DINO DIVULGADOR DE NOTÍCIAS São José dos Campos–(DINO – 14 jul, 2023) – Nem sempre se exploram todas as facilidades que a tecnologia oferece. Os dispositivos ‘assistentes
Saiba Mais